Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2022 Earnings Call Transcript

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2022 Earnings Conference Call October 27, 2022 8:30 AM ET

Company Participants

Christine Lindenboom - Senior Vice President, Investor Relations and Corporate Communications

Yvonne Greenstreet - Chief Executive Officer

Tolga Tanguler - Chief Commercial Officer

Akshay Vaishnaw - President

Jeff Poulton - Chief Financial Officer

Conference Call Participants

Maury Raycroft - Jefferies

Salveen Richter - Goldman Sachs

Tazeen Ahmad - Bank of America

Eliana Merle - UBS

Ritu Baral - Cowen

Jessica Fye - JPMorgan

David Lebowitz - Citi

Gena Wang - Barclays

Paul Matteis - Stifel

Gary Nachman - BMO

Luca Issi - RBC Capital

Joseph Stringer - Needham & Company

Myles Minter - William Blair

Operator

Thank you for standing by and welcome to the Alnylam Pharmaceuticals Third Quarter 2022 Financial Results Conference Call. [Operator Instructions] As a reminder, today’s conference call is being recorded. I would now like to turn the conference over to the company. Please go ahead.

Christine Lindenboom

Good morning. I am Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. With me today on the phone are Yvonne Greenstreet, Chief Executive Officer; Tolga Tanguler, Chief Commercial Officer; Akshay Vaishnaw, President; and Jeff Poulton, Chief Financial Officer. For those of you participating via conference call, the accompanying slides can be accessed by going to the Events section of the Investors page for website, investors.alnylam.com/events.

During today’s call, as outlined on Slide 2, Yvonne will offer introductory remarks and provide some general context. Tolga will provide an update on our global commercial progress, Akshay will review early pipeline updates and clinical progress, and Jeff will review our financials and guidance, followed by a summary of upcoming milestones before we open the call to your questions.

I’d like to remind you that this call will contain remarks from turning on Alnylam’s future expectations, plans, prospects, which constitute forward-looking statements for the purposes of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recently quarterly report on file with the SEC. In addition, any forward-looking statements represent our views as only as the date of this report and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update such statements.